Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,017

Document Document Title
WO/2019/108824A1
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.  
WO/2019/088270A1
The present invention provides a compound that is highly safe and that is useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical compos...  
WO/2019/047493A1
The present invention relates to an ionic liquid, a cation of which contains a hexafluoroisopropylsulfonic acid group. The ionic liquid provided by the present invention introduces a hexafluoroisopropylsulfonic acid group into a cationic...  
WO/2019/027941A1
The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.  
WO/2019/020016A1
Disclosed are a CA-4 antitumour drug, a synthesis method and the use thereof. The CA-4 antitumour drug introduces an alkoxy group or a fluorine-containing alkoxy group at the 4' position of a natural product, i.e., combretastatin, and ca...  
WO/2019/004114A1
Provided is a production method for efficiently synthesizing a compound (1-2) which is an important intermediate in production of edoxaban. The method comprises dripping a compound (1-1) into a solution A that is obtained by causing a re...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/094233A3
Dimethylamine (Me2NH) is reacted with sulfuryl fluoride (S02F2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FS02NMe2), tetramethylsulfamide (S02(NMe2)2), or a combination thereof. A second phase, which may...  
WO/2018/094233A2
Dimethylamine (Me2NH) is reacted with sulfuryl fluoride (S02F2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FS02NMe2), tetramethylsulfamide (S02(NMe2)2), or a combination thereof. A second phase, which may...  
WO/2018/018091A1
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.  
WO/2017/217553A1
[Problem] To provide a novel agricultural chemical, and particularly an herbicide. [Solution] An oxime compound represented by formula (1) and an herbicide containing the same. (In formula (1): B represents B-1 or the like; Q represents ...  
WO/2017/150903A1
The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the p...  
WO/2017/140778A1
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently...  
WO/2017/067837A1
Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, A, X and Y are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparatio...  
WO/2017/059446A1
Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and meth...  
WO/2017/031599A1
A quaternary ammonium sulfonamide compound of formula (I): wherein R = (II), C1-C3 linear or branched alkyl, R1 and R2 are the same or different and selected from C1 to C18 linear or branched alkyl, R3 and R4 are the same or different an...  
WO/2016/172424A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)  
WO/2016/128885A1
The present invention provides novel intermediates of cobicistat or a pharmaceutically acceptable salt thereof and a process for its preparation. The present invention also provides for the preparation of cobicistat or a pharmaceutically...  
WO/2016/094897A1
Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a com...  
WO/2016/082052A1
The invention relates to compounds derived from 2-phenyl-fluorosulfonamides of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and claims, and to a method for producing said compounds by preparing a solution with ...  
WO/2015/187929A1
Described herein are methods for the treatment of fragile X syndrome and other cognitive disorders related to impairment of mGluR-dependent LTD and/or FMRP gene dysfunction by administration of an agent that inhibits the Cdhl-APC complex.  
WO/2015/077451A1
The present invention relates to N-phenyl carbamate derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.  
WO/2015/039172A1
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.  
WO/2015/007206A1
The present invention relates to novel afatinib acid addition salts and crystal forms thereof. Compared with the prior art, the afatinib acid addition salts and crystal forms thereof of the present invention have one or more improved pro...  
WO/2014/210436A3
Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacothe...  
WO/2014/157653A1
The present invention addresses the problem of providing an efficient process for preparing important intermediate compounds (1) and (1a) for the production of FXa inhibitors (X) and (X-a). The present invention pertains to: a process wh...  
WO/2014/140059A1
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the co...  
WO/2014/096864A1
The present subject matter relates generally to compounds having the formula (I): wherein each of X, Y, R1, R2, R3, R4, and n are as defined herein. Compounds of formula (I) may act as inhibitors of the thioredoxin reductase enzyme syste...  
WO/2014/096864A9
The present subject matter relates generally to compounds having the formula (I): wherein each of X, Y, R1, R2, R3, R4, and n are as defined herein. Compounds of formula (I) may act as inhibitors of the thioredoxin reductase enzyme syste...  
WO/2014/057498A3
The present invention relates to cobicistat intermediates, processes and further conversion to cobicistat with improved yield and quality.  
WO/2014/057498A2
The present invention relates to cobicistat intermediates, processes and further conversion to cobicistat with improved yield and quality.  
WO/2014/008458A3
The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described ...  
WO/2013/191144A1
A novel indanesulfamide compound, such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]- sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H- inden-1-yl]sulfamide and (+)-N-(2,2,4,6,7- pentafluoro-2,3-dihydro-1H-inden-1-yl)sul...  
WO/2013/102826A1
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...  
WO/2013/088315A1
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...  
WO/2013/039187A1
[Problem] To provide a compound useful as a renal disease preventive and/or therapeutic agent. [Solution] The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoi...  
WO/2012/131142A1
The present invention relates to the use of a group of sulphamide derivatives with neuroprotective capacity that are of use in the treatment and/or prevention of diseases associated with cell death, such as Alzheimer's disease, Parkinson...  
WO/2012/134233A2
Provided is a sulphamide derivative having an adamantyl group, represented by the accompanying chemical formula 1, or a pharmaceutically acceptable salt thereof. The sulphamide derivative suppresses the activity of 11β-hydroxysteroid de...  
WO/2012/134233A3
Provided is a sulphamide derivative having an adamantyl group, represented by the accompanying chemical formula 1, or a pharmaceutically acceptable salt thereof. The sulphamide derivative suppresses the activity of 11β-hydroxysteroid de...  
WO/2012/122969A1
Triazene-substituted diphenyl derivatives are suitable as chemotherapeutic agents for treating carcinomas in humans and animals.  
WO/2012/074784A2
Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy,...  
WO/2011/118672A1
Disclosed is a pharmaceutical product, particularly a pharmaceutical composition having a plasma kallikrein inhibition activity and is useful as a prophylactic or therapeutic agent for edemas (particularly hereditary vascular edema and c...  
WO/2011/076784A3
The present invention relates to a compound of formula (I): Formula (I), wherein: - n is 0, 1 or 2; - A is in particular CH or N; - X is in particular CO, SO2, CS, and R1 is in particular H, - R2 is a group of formula NR3R4 or OR5, R3 an...  
WO/2011/047788A1
The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and ...  
WO/2011/048152A1
The present invention relates to novel lithium salts which comprise pentafluorophenylamide anions and are of the general formula Li+[N(SO2-R)(C6F5)]-, which are optionally present as solvent-free complexes. R is selected from fluorine, l...  
WO/2011/047796A1
The present invention relates to substituted halophenoxybenzamide derivative compounds of general formula (I) in which R1, R2, R3, R3a, R4, R5, R6, Ra, Rb, Rc, and X are as defined in the claims, to methods of preparing said compounds, t...  
WO/2010/122968A1
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...  
WO/2010/113835A1
Disclosed is a method for producing "a salt or a complex comprising imidic acid and an organic base", characterized by reacting halogenated sulfuryl or halogenated phosphoryl with ammonia in the presence of an organic base. According to ...  
WO/2010/115000A3
The invention provides methods and intermediates that are useful for preparing a compound of formula (I).  
WO/2010/115000A2
The invention provides methods and intermediates that are useful for preparing a compound of formula I.  

Matches 1 - 50 out of 1,017